Cryofocus Medtech (Shanghai) Co. Ltd. Class H

As of December 31, 2025, Cryofocus Medtech (Shanghai) Co. Ltd. Class H carries a market capitalization of 1.65B, placing it among publicly traded companies globally. Its enterprise value stands at 1.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cryofocus Medtech (Shanghai) Co. Ltd. Class H's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, Cryofocus Medtech (Shanghai) Co. Ltd. Class H has 239.11M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Cryofocus Medtech (Shanghai) Co. Ltd. Class H maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Cryofocus Medtech (Shanghai) Co. Ltd. Class H's stock has declined approximately 64.39% over the past 52 weeks. The 50-day moving average sits at 2.99, while the 200-day moving average is 4.65.

As of December 31, 2025, Cryofocus Medtech (Shanghai) Co. Ltd. Class H holds 38.99M in cash and equivalents against 29.16M in total debt, resulting in a net debt position of -24.38M. Total book value stands at 55.35M, with working capital of 34.49M providing operational flexibility.